These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2914287)

  • 1. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; Koller CA; McCredie KB; Freireich EJ
    Cancer; 1989 Mar; 63(5):813-7. PubMed ID: 2914287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.
    Stewart JA; Cassileth PA; Bennett JM; O'Connell MJ
    Am J Clin Oncol; 1988 Dec; 11(6):627-9. PubMed ID: 3189228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
    Coonley CJ; Warrell RP; Young CW
    Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
    O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
    Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of homoharringtonine administered by prolonged continuous infusion.
    Neidhart JA; Young DC; Kraut E; Howinstein B; Metz EN
    Cancer Res; 1986 Feb; 46(2):967-9. PubMed ID: 3940656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of homoharringtonine.
    Neidhart JA; Young DC; Derocher D; Metz EN
    Cancer Treat Rep; 1983 Sep; 67(9):801-4. PubMed ID: 6883357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine: a phase I evaluation.
    Stewart JA; Krakoff IH
    Invest New Drugs; 1985; 3(3):279-86. PubMed ID: 4066221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
    Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
    Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.
    Runge-Morris MA; Kies MS; Vokes E; Blough R; Weidner L; Knop R; Rowland K
    Invest New Drugs; 1989 Jul; 7(2-3):269-73. PubMed ID: 2793384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
    Daver N; Vega-Ruiz A; Kantarjian HM; Estrov Z; Ferrajoli A; Kornblau S; Verstovsek S; Garcia-Manero G; Cortes JE
    Eur J Cancer Care (Engl); 2013 Sep; 22(5):605-11. PubMed ID: 23701251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
    Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
    J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
    Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
    Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
    O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
    Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.